D iabetes mellitus (DM) has been termed a "coronary disease equivalent", yet data suggest that only those DM subjects with metabolic syndrome (MetS) are at increased coronary risk.
Introduction
Due to an ageing population, increasing obesity and decreasing leisure-time physical activity, the global prevalence of the metabolic syndrome (MetS) and type 2 diabetes mellitus (DM) continues to increase at alarming rates. 1 With the US prevalence of DM exceeding 6% of the adult population, 2 and MetS affecting approximately one in four US adults, 3, 4 continued efforts to understand the complex relationship between MetS, DM and atherosclerotic heart disease (ASHD) risk remain a public health imperative with important therapeutic implications.
Diabetes is independently associated with increased cardiovascular disease (CVD) risk, with a magnitude of association similar to that observed for prevalent coronary heart disease (CHD). 5, 6 The metabolic syndrome, a clustering of cardiovascular risk factors associated with insulin resistance and obesity that affects up to 85% of patients with type 2 DM, [7] [8] [9] has similarly been associated with increased risk for subsequent cardiovascular complications. [10] [11] [12] [13] [14] [15] [16] [17] However, the common co-existence of DM and MetS confounds the interpretation of these observations with regard to their independent and joint associations with CVD risk, as most analyses have not been independently stratified according to DM and MetS status. Analyses using data from the National Health and Nutrition Examination Survey (NHANES) program 9 and from the Chinese Multi-provincial Cohort Study (CMCS) 18 revealed that the association with CVD risk was limited to the MetS, either alone or concomitant with DM, whereas DM in the absence of MetS was not statistically associated with incremental CVD risk. However, the former study is limited by only six prevalent CVD cases in the subgroup with DM in the absence of MetS, and the latter is limited by its inclusion only of Chinese subjects with uncertain generalisability to a Western, multi-ethnic population. A third study that analysed the independent and joint associations between MetS, DM and CVD derives from the San Antonio Heart Study (SAHS), the largest study published to date reporting such analyses. 19 In that study, patients with either DM alone or MetS alone had increased rates of CVD mortality compared with patients with neither condition, but these trends were not statistically significant, possibly owing to limitations in statistical power due to the low number of observed events. In contrast, subjects with both DM and MetS had a statistically significant increased risk of cardiovascular mortality compared with those with neither condition (odds ratios [OR] =2.5, 95% confidence intervals [CI] 1.40-4.52 in men; OR=9.36, 95% CI 4.36-20.3 in women). Therefore, based on these prior reports, uncertainty remains with regard to the relative influence that MetS and DM may have on atherosclerotic disease risk.
Using data from the Dallas Heart Study (DHS), a large population-based, probability sample of adults living in Dallas County, we sought to analyse the independent and joint associations between MetS, DM and atherosclerosisthe requisite precursor to CVD complications -using stateof-the-art imaging of subclinical atherosclerosis by cardiac electron-beam computed tomography scanning to detect coronary artery calcium (CAC) and magnetic resonance imaging (MRI) to assess abdominal aortic plaque (AAP).
Research design and methods

Study population
The Dallas Heart Study is a multi-ethnic, population-based, probability sample of Dallas County residents aged 30 to 65 years; the study design has been published previously. 20 Data collection included medical history, measurement of anthropometric data and blood pressure (n=6,101), collection of a single sample at study entry of blood and urine (n=3,398), and multiple imaging studies, including electron beam computed tomography (EBCT) for the assessment of CAC and abdominal MRI for assessment of AAP (n=2,871). The present analyses include data on the 2,735 subjects who completed all phases of the DHS and had complete clinical, laboratory and EBCT data. For the AAP analyses, 2,246 participants had complete study data and had adequate MRI imaging data. The study protocol was approved by the University of Texas Southwestern Medical Center Institutional Review Board and all participants provided their written informed consent.
Study definitions
Diabetes mellitus was defined by either self-report accompanied by use of anti-hyperglycaemic medication; or by elevated serum glucose (fasting > 126 mg/dL [7.0 mmol/L]; or by non-fasting glucose > 200 mg/dL [11.1 mmol/L]). 21 MetS was defined according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III) criteria that require the presence of > 3 of the following: 1) increased waist circumference (> 40 in [> 102 cm] for men; > 35 in [> 88 cm] for women); 2) elevated triglycerides (> 150 mg/dL [1.69 mmol/L]); 3) low high-density lipoprotein (HDL) cholesterol (< 40 mg/dL [1.04 mmol/L] in men, < 50 mg/dL [1.29 mmol/L] in women); 4) elevated blood pressure (> 130/> 85 mmHg) or medically-treated hypertension; and 5) impaired fasting glucose (> 100 mg/dL [5.6 mmol/L]) or medically treated diabetes. 7 Race/ethnicity was defined by subject self-report. Body mass index (BMI) was calculated based on measured height and weight at study entry. Blood pressure was measured at study entry using an automated system (Welch Allyn Inc., Skaneateles Falls, NY, US), with five consecutive measurements obtained, and reported as the mean of the final three recordings. Hypertension was defined as one of the following: systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg or the use of anti-hypertensive medication. Hypercholesterolaemia was defined as calculated low-density lipoprotein cholesterol (LDL-C) > 160 mg/dL (4.1 mmol/L) on a fasting sample, direct LDL-C > 160 mg/dL (4.1 mmol/L) on a non-fasting sample, total cholesterol > 200 mg/dL (5.2 mmol/L) or use of statin medication.
Smoking status was categorised as "current smoker" or "former smoker/never smoked".
Study assessments
Cardiovascular imaging Cardiac electron-beam computed tomography (EBCT) scanning was performed using an Imatron C-150XP EBCT scanner with 3-mm slices; duplicate scans were performed within one to two minutes. The Agatston method was used to determine CAC scores, 22 and recorded as the average of the two scans. Due to the extreme skewness of the Agatston score distribution, CAC was analysed as a categorical variable, with prevalent CAC defined by an Agatston score > 10, a previously published data-derived threshold that optimises the signal-tonoise ratio to minimise false-positive rates. 23 In short, EBCT measurements of CAC are complicated by X-ray scattering due to obesity and interference from adjacent tissues. Therefore, to reduce the false-positive rate of CAC classification, duplicate scans are analysed for concordance with a high interscan variability in CAC scores observed within the range of 0-10 yielding the data-derived specificity threshold for prevalent CAC at > 10 Agatston units with > 95% concordance above this threshold.
Abdominal aorta MRI scanning was performed using a 1.5-T whole-body MRI system (Intera, Phillips Medical Systems). Six transverse slices of the infrarenal abdominal aorta were obtained with a free-breathing, ECG-gated, T2weighted turbo spin-echo (black-blood) sequence. Images were analysed with the Magnetic Resonance Analytical Software Systems cardiac analysis software package (version 4.2 beta, Medis Medical Imaging Systems Inc.) by personnel blinded to all participant data. Abdominal aortic plaque was characterised as areas of hyperintense signal, luminal protrusion or focal wall thickening, as previously described, 24, 25 and was dichotomously defined as present or absent.
Statistical analysis
Categorical data are expressed as proportions and continuous data as means + SD. Inter-group comparisons were performed with Kruskal-Wallis and Pearson's tests where appropriate. Univariable and multivariable logistic regression techniques were used to analyse the individual and joint associations between MetS and DM and prevalent CAC and prevalent AAP. Covariates used in the multivariable models included: age, sex, ethnicity (Caucasian, Hispanic, African-American, other), prevalent hypercholesterolaemia, hypertension and current smoking. In addition, formal MetS-by-DM interaction testing was performed for the associations with CAC and AAP using multivariable logistic regression. All analyses were performed using the STATA (Version 9) statistical software package; 2-tailed p-values < 0.05 were deemed statistically significant, without adjustment for multiple comparison.
Results
Overall, MetS was present in 943 subjects (34.5%) and DM in 299 (10.9%), including 697 with MetS only (25.5%), 53 with DM only (1.9%) and 246 with both MetS and DM (9.0%). Baseline characteristics according to MetS and DM status are presented in table 1. Overall, prevalent CAC was present in 581 subjects (21.2%) and prevalent AAP in 908 (40.4%). As shown in figure 1 , the crude prevalence of CAC increased in a stepwise fashion from the subgroup with nei- Qualitatively similar association trends were observed between MetS, DM and AAP, but after multivariable adjustment, neither MetS nor DM remained independently associated with AAP, and no MetS-by-DM interaction with AAP was evident (interaction p=0.52).
Discussion
The principal observations in the present study comprising a contemporary, urban, multi-ethnic sample of US adults are that: a) MetS and DM affect a large proportion of the adult population; b) both MetS and DM are independently associated with an increased prevalence of subclinical coronary atherosclerosis, with similar trends evident for abdominal aortic plaque; and c) the magnitude of the association with atherosclerosis is strongest for those subjects who have concomitant MetS and DM.
Numerous studies have reported an association between MetS and cardiovascular outcomes, many of which are limited by no or limited adjustment for the presence of DM. 12, 13, 17, 19, [26] [27] [28] [29] However, few studies have rigorously assessed the independent and joint associations between MetS, DM and atherosclerosis. Such analyses from NHANES suggested that the presence of MetS with or without concomitant DM was associated with prevalent coronary heart disease (CHD), but DM without MetS was not; 9 similarly, in the Chinese Multi-provincial Cohort Study, MetS was significantly associated with all CVD outcomes assessed, whereas DM without MetS was only associated with stroke. 18 To the contrary and concordant with the present observations, observations from the San Antonio Heart Study (SAHS) suggested trends toward independent associations between both MetSyn, DM and cardiovascular (CV) mortality, with the presence of both conditions independently associated with increased CV mortality risk for both men (OR=2.5, 95% CI 1.40-4.52) and women (OR=9.36, 95% CI 4.36-20.3). 19 A number of considerations may contribute to the disparate results between prior studies and the present observations. In contrast to analysis of clinical coronary heart disease, the present study assessed subclinical atherosclerosis burden and it remains possible that the associations between MetS, DM and clinical CVD events differ for disease development and progression (i.e. atheroma burden). The coexistence of DM and MetS may be a particularly important contributor to the transition from subclinical to clinical atherosclerosis. While some of the aforementioned studies may report discordant observations on the individual associations between MetS, DM and cardiovascular disease, the same studies are unambiguous in confirming the influence of combined MetS and DM on clinical events. This association may be mediated by an increased burden of atherosclerosis, but also could in part be mediated by pro-inflammatory, pro-oxidative and pro-thrombotic perturbations associated with both conditions. For example, in our study, concentrations of circulating high-sensitivity C-reactive protein (hs-CRP) were elevated in subjects with MetS and highest in those with MetS with concomitant DM.
Some have speculated that conditions of hyperglycaemia may accelerate arterial calcification that involves the media as well as the intima, and that CAC quantification among patients with DM may overestimate atheroma burden (and therefore, CVD risk) compared with non-DM individuals. 30, 31 If valid, this phenomenon could contribute to the discordant observations between our study and the prior data from NHANES and CMCS. However, autopsy analysis has demonstrated quantitatively similar amounts of calcium indexed to atheroma area, 32 and at least one study has demonstrated an association between measures of CAC and subsequent CVD risk commensurate with those observed in non-DM cohorts. 33 In addition, the qualitatively consistent trends observed in the present study for AAP (a measure of atheroma burden not dependent on calcification) support the conclusion that DM is associated with atherosclerosis even when MetS is not present. An interesting observation from the present study that was also evident in the study from NHANES is that the subset with DM but no MetS had a notably low-risk CVD risk profile. 9 Despite the fact that the subgroup with only DM in the present study was older, with a greater proportion of men and smokers, the remainder of the CVD risk profile was qualitatively most similar to the subset with neither MetS nor DM and comprised the lowest average LDL (98 mg/dL [2.5382 mmol/L]), the highest average HDL (59 mg/dL [1.5281 mmol/L]), and the lowest triglyceride (91 mg/dL [0.02739 mmol/L]) levels of all other subgroups. Despite this relatively modest CVD risk profile, however, the group with DM but no MetS had a significantly higher prevalence of CAC and AAP compared with both those with neither disorder and those with the MetS only. This finding would seem to implicate hyperglycaemia as a causative factor in atherosclerosis, a hypothesis supported by the association between type 1 DM and atherosclerosis, 34 as the association with CVD risk is less confounded in type 1 versus type 2 DM by age or the clustering of risk factors. Indeed, in type 1 diabetes a graded association observed with CAC has been reported according to indices of worsening glycaemic control. [34] [35] [36] [37] [38] Because only 53 subjects were in the DM without MetS group, these observations should be interpreted with appropriate caution and further investigation is needed to characterise better this small but clinically interesting subset of subjects.
Several limitations of this study should be noted. First, the study is a cross-sectional analysis of a large and ethnically diverse cohort and therefore may not be applicable to other populations. Furthermore, our outcome measures were surrogate measures of CAC and AAP rather than clinical events. The limited sample size in certain subgroups, especially those with DM but without MetS (n=53), undermines statistical power and precision and limits the depth of multivariable analyses that could be performed. Additionally, within the cohort, there was no assessment of glycosylated haemoglobin and the duration of DM was unknown, which results in incomplete characterisation of DM status. Finally, the absence of systematic surveillance for abnormalities of glucose metabolism results in certain likelihood for misclassification error for both the presence of MetS and for DM; however, this misclassification would bias our results toward the null and therefore may actually lead to an underestimation of the associations reported.
Conclusions
In this study, DM and MetS were found to be independently associated with prevalent CAC and AAP. Furthermore, when both MetS and DM were present, the prevalence of atherosclerosis was significantly greater than if either condition alone was present. These observations suggest: 1) cardiovascular risk modification for those with MetS, even in the absence of DM, may warrant an intensity similar to that presently recommended for those with DM; 2) even in the absence of MetS, DM is associated with increased coronary atherosclerosis, underscoring the importance of CVD riskmodifying interventions in this subset of patients; and 3) the concomitant presence of MetS and DM should be considered an especially high-risk situation warranting the most aggressive of CVD risk interventions.
